Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Shabir Madhi and Gaurav Kwatra.
Shabir Madhi
Connection Strength
10,967
Gaurav Kwatra
  1. Prevalence of group B Streptococcus colonisation in mother-newborn dyads in low-income and middle-income south Asian and African countries: a prospective, observational study. Lancet Microbe. 2024 Aug 20; 100897.
    View in: PubMed
    Score: 0,951
  2. Correlation of dried blood spots and plasma for quantification of Immunoglobulin (IgG) against Receptor binding domain and full length spike protein of SARS-CoV-2. J Virol Methods. 2022 02; 300:114394.
    View in: PubMed
    Score: 0,788
  3. Prevalence of maternal colonisation with group B streptococcus: a systematic review and meta-analysis. Lancet Infect Dis. 2016 09; 16(9):1076-1084.
    View in: PubMed
    Score: 0,537
  4. Serotype-Specific Cell-Mediated Immunity Associated With Clearance of Homotypic Group B Streptococcus Rectovaginal Colonization in Pregnant Women. J Infect Dis. 2016 06 15; 213(12):1923-6.
    View in: PubMed
    Score: 0,532
  5. Natural acquired humoral immunity against serotype-specific group B Streptococcus rectovaginal colonization acquisition in pregnant women. Clin Microbiol Infect. 2015 Jun; 21(6):568.e13-21.
    View in: PubMed
    Score: 0,492
  6. Serotype-specific acquisition and loss of group B streptococcus recto-vaginal colonization in late pregnancy. PLoS One. 2014; 9(6):e98778.
    View in: PubMed
    Score: 0,471
  7. Surface protein distribution in Group B Streptococcus isolates from South Africa and identifying vaccine targets through in silico analysis. Sci Rep. 2024 09 30; 14(1):22665.
    View in: PubMed
    Score: 0,240
  8. Vaccine value profile for Klebsiella pneumoniae. Vaccine. 2024 Jul 25; 42(19S1):S125-S141.
    View in: PubMed
    Score: 0,231
  9. Potential for Maternally Administered Vaccine for Infant Group B Streptococcus. N Engl J Med. 2023 Jul 20; 389(3):215-227.
    View in: PubMed
    Score: 0,221
  10. Immune responses against group B Streptococcus monovalent and pentavalent capsular polysaccharide tetanus toxoid conjugate vaccines in Balb/c mice. iScience. 2023 Aug 18; 26(8):107380.
    View in: PubMed
    Score: 0,220
  11. Efficacy of primary series AZD1222 (ChAdOx1 nCoV-19) vaccination against SARS-CoV-2 variants of concern: Final analysis of a randomized, placebo-controlled, phase 1b/2 study in South African adults (COV005). Vaccine. 2023 05 26; 41(23):3486-3492.
    View in: PubMed
    Score: 0,217
  12. Sustained Low Incidence of Severe and Fatal COVID-19 Following Widespread Infection Induced Immunity after the Omicron (BA.1) Dominant in Gauteng, South Africa: An Observational Study. Viruses. 2023 02 21; 15(3).
    View in: PubMed
    Score: 0,214
  13. Association of infant Rib and Alp1 surface protein N-terminal domain immunoglobulin G and invasive Group B Streptococcal disease in young infants. Vaccine. 2023 03 03; 41(10):1679-1683.
    View in: PubMed
    Score: 0,214
  14. Antepartum SARS-CoV-2 infection and adverse birth outcomes in South African women. J Glob Health. 2022 Dec 03; 12:05050.
    View in: PubMed
    Score: 0,211
  15. Active Intrapartum SARS-CoV-2 Infection and Pregnancy Outcomes. Am J Perinatol. 2022 12; 39(S 01):S42-S48.
    View in: PubMed
    Score: 0,210
  16. T-cell responses induced by ChAdOx1 nCoV-19 (AZD1222) vaccine to wild-type severe acute respiratory syndrome coronavirus 2 among people with and without HIV in South Africa. AIDS. 2023 01 01; 37(1):105-112.
    View in: PubMed
    Score: 0,209
  17. Durability of ChAdOx1 nCoV-19 (AZD1222) vaccine and hybrid humoral immunity against variants including omicron BA.1 and BA.4 6 months after vaccination (COV005): a post-hoc analysis of a randomised, phase 1b-2a trial. Lancet Infect Dis. 2023 03; 23(3):295-306.
    View in: PubMed
    Score: 0,209
  18. Maternal-foetal transfer of severe acute respiratory syndrome coronavirus 2 antibodies among women with and those without HIV infection. AIDS. 2022 11 01; 36(13):1777-1782.
    View in: PubMed
    Score: 0,207
  19. Estimated SARS-CoV-2 infection rate and fatality risk in Gauteng Province, South Africa: a population-based seroepidemiological survey. Int J Epidemiol. 2022 05 09; 51(2):404-417.
    View in: PubMed
    Score: 0,203
  20. Population Immunity and Covid-19 Severity with Omicron Variant in South Africa. N Engl J Med. 2022 04 07; 386(14):1314-1326.
    View in: PubMed
    Score: 0,200
  21. Infant serotype specific anti-capsular immunoglobulin G antibody and risk of invasive group B Streptococcal disease. Vaccine. 2021 11 16; 39(47):6813-6816.
    View in: PubMed
    Score: 0,195
  22. T-cell responses to SARS-CoV-2 in unexposed South African women. Gates Open Res. 2021; 5:150.
    View in: PubMed
    Score: 0,195
  23. Investigation of Possible Nosocomial-Associated Invasive Group B Streptococcus Disease Using Whole-Genome Sequencing: A Report of 3 Cases. J Pediatric Infect Dis Soc. 2021 Sep 23; 10(8):880-882.
    View in: PubMed
    Score: 0,194
  24. Association of Group B Streptococcus (GBS) Serum Serotype-Specific Anticapsular Immunoglobulin G Concentration and Risk Reduction for Invasive GBS Disease in South African Infants: An Observational Birth-Cohort, Matched Case-Control Study. Clin Infect Dis. 2021 09 07; 73(5):e1170-e1180.
    View in: PubMed
    Score: 0,194
  25. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial. Lancet HIV. 2021 09; 8(9):e568-e580.
    View in: PubMed
    Score: 0,193
  26. Effect of cytomegalovirus infection on humoral immune responses to select vaccines administered during infancy. Vaccine. 2021 08 09; 39(34):4793-4799.
    View in: PubMed
    Score: 0,192
  27. Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant. N Engl J Med. 2021 05 20; 384(20):1885-1898.
    View in: PubMed
    Score: 0,187
  28. Hemagglutinin Stalk Antibody Responses Following Trivalent Inactivated Influenza Vaccine Immunization of Pregnant Women and Association With Protection From Influenza Virus Illness. Clin Infect Dis. 2020 08 14; 71(4):1072-1079.
    View in: PubMed
    Score: 0,180
  29. The Association Between Breast Milk Group B Streptococcal Capsular Antibody Levels and Late-onset Disease in Young Infants. Clin Infect Dis. 2020 03 03; 70(6):1110-1114.
    View in: PubMed
    Score: 0,175
  30. Prevalence of Congenital Cytomegalovirus Infection and Associated Risk of In Utero Human Immunodeficiency Virus (HIV) Acquisition in a High-HIV Prevalence Setting, South Africa. Clin Infect Dis. 2019 10 30; 69(10):1789-1796.
    View in: PubMed
    Score: 0,170
  31. Association between antibodies against group B Streptococcus surface proteins and recto-vaginal colonisation during pregnancy. Sci Rep. 2017 11 28; 7(1):16454.
    View in: PubMed
    Score: 0,149
  32. Reduced Transplacental Transfer of Group B Streptococcus Surface Protein Antibodies in HIV-infected Mother-Newborn Dyads. J Infect Dis. 2017 02 01; 215(3):415-419.
    View in: PubMed
    Score: 0,141
  33. Vaccination of HIV-infected pregnant women: implications for protection of their young infants. Trop Dis Travel Med Vaccines. 2017; 3:1.
    View in: PubMed
    Score: 0,140
  34. Temporal Changes in Invasive Group B Streptococcus Serotypes: Implications for Vaccine Development. PLoS One. 2016; 11(12):e0169101.
    View in: PubMed
    Score: 0,140
  35. Group B Streptococcus: developing a correlate of protection for a vaccine against neonatal infections. Curr Opin Infect Dis. 2016 06; 29(3):262-7.
    View in: PubMed
    Score: 0,135
  36. Correlates of protection of serotype-specific capsular antibody and invasive Group B Streptococcus disease in South African infants. Vaccine. 2015 Nov 27; 33(48):6793-9.
    View in: PubMed
    Score: 0,129
  37. Association between maternal Group B Streptococcus surface-protein antibody concentrations and invasive disease in their infants. Expert Rev Vaccines. 2015; 14(12):1651-60.
    View in: PubMed
    Score: 0,128
  38. HIV-1 Is Associated With Lower Group B Streptococcus Capsular and Surface-Protein IgG Antibody Levels and Reduced Transplacental Antibody Transfer in Pregnant Women. J Infect Dis. 2015 Aug 01; 212(3):453-62.
    View in: PubMed
    Score: 0,123
  39. Review on the association of Group B Streptococcus capsular antibody and protection against invasive disease in infants. Expert Rev Vaccines. 2015 Jan; 14(1):135-49.
    View in: PubMed
    Score: 0,120
  40. Evaluation of Trans-Vag broth, colistin-nalidixic agar, and CHROMagar StrepB for detection of group B Streptococcus in vaginal and rectal swabs from pregnant women in South Africa. J Clin Microbiol. 2013 Aug; 51(8):2515-9.
    View in: PubMed
    Score: 0,109
  41. T-cell responses to ancestral SARS-CoV-2 and Omicron variant among unvaccinated pregnant and postpartum women living with and without HIV in South Africa. Sci Rep. 2024 09 02; 14(1):20348.
    View in: PubMed
    Score: 0,060
  42. Distributions of candidate vaccine Targets, virulence Factors, and resistance features of invasive group B Streptococcus using Whole-Genome Sequencing: A Multicenter, population-based surveillance study. Vaccine. 2024 Jun 11; 42(16):3564-3571.
    View in: PubMed
    Score: 0,058
  43. Interlaboratory comparison of a multiplex immunoassay that measures human serum IgG antibodies against six-group B streptococcus polysaccharides. Hum Vaccin Immunother. 2024 Dec 31; 20(1):2330138.
    View in: PubMed
    Score: 0,058
  44. Post-acute sequelae of SARS-CoV-2 infection in health care workers from South Africa. Oxf Open Immunol. 2024; 5(1):iqae001.
    View in: PubMed
    Score: 0,058
  45. ChAdOx1 nCoV-19 (AZD1222) vaccine-induced Fc receptor binding tracks with differential susceptibility to COVID-19. Nat Immunol. 2023 07; 24(7):1161-1172.
    View in: PubMed
    Score: 0,055
  46. Longitudinal IgA and IgG Response, and ACE2 Binding Blockade, to Full-Length SARS-CoV-2 Spike Protein Variants in a Population of Black PLWH Vaccinated with ChAdOx1 nCoV-19. Viruses. 2023 02 06; 15(2).
    View in: PubMed
    Score: 0,053
  47. Emergence and phenotypic characterization of the global SARS-CoV-2 C.1.2 lineage. Nat Commun. 2022 04 08; 13(1):1976.
    View in: PubMed
    Score: 0,050
  48. AstraZeneca COVID-19 vaccine induces robust broadly cross-reactive antibody responses in Malawian adults previously infected with SARS-CoV-2. BMC Med. 2022 03 28; 20(1):128.
    View in: PubMed
    Score: 0,050
  49. Estimation of invasive Group B Streptococcus disease risk in young infants from case-control serological studies. BMC Med Res Methodol. 2022 03 27; 22(1):85.
    View in: PubMed
    Score: 0,050
  50. SARS-CoV-2 Omicron Symptomatic Infections in Previously Infected or Vaccinated South African Healthcare Workers. Vaccines (Basel). 2022 Mar 17; 10(3).
    View in: PubMed
    Score: 0,050
  51. The antimicrobial activity of zinc against group B Streptococcus is strain-dependent across diverse sequence types, capsular serotypes, and invasive versus colonizing isolates. BMC Microbiol. 2022 01 13; 22(1):23.
    View in: PubMed
    Score: 0,050
  52. SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses. Cell. 2022 02 03; 185(3):467-484.e15.
    View in: PubMed
    Score: 0,050
  53. Severe Acute Respiratory Syndrome Coronavirus 2 Infection Among Healthcare Workers in South Africa: A Longitudinal Cohort Study. Clin Infect Dis. 2021 11 16; 73(10):1896-1900.
    View in: PubMed
    Score: 0,049
  54. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet. 2021 03 06; 397(10277):881-891.
    View in: PubMed
    Score: 0,047
  55. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021 01 09; 397(10269):99-111.
    View in: PubMed
    Score: 0,046
  56. Systematic review of Group B Streptococcal capsular types, sequence types and surface proteins as potential vaccine candidates. Vaccine. 2020 10 07; 38(43):6682-6694.
    View in: PubMed
    Score: 0,045
  57. Antimicrobial susceptibility and serotype distribution of Streptococcus agalactiae rectovaginal colonising isolates from pregnant women at a tertiary hospital in Pretoria, South Africa: An observational descriptive study. S Afr Med J. 2020 Aug 31; 110(9):869-871.
    View in: PubMed
    Score: 0,045
  58. Rubella seroprevalence in pregnant women living with and without HIV in Soweto, South Africa. Int J Infect Dis. 2020 Feb; 91:255-260.
    View in: PubMed
    Score: 0,043
  59. Measles seroprevalence in pregnant women in Soweto, South Africa: a nested cohort study. Clin Microbiol Infect. 2020 Apr; 26(4):515.e1-515.e4.
    View in: PubMed
    Score: 0,043
  60. Serocorrelates of protection against infant group B streptococcus disease. Lancet Infect Dis. 2019 05; 19(5):e162-e171.
    View in: PubMed
    Score: 0,040
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.